Edaravone's Safety Profile in Acute Ischemic Stroke
2024

Safety of Edaravone in Acute Ischemic Stroke

Sample size: 64 publication Evidence: moderate

Author Information

Author(s): Batino Laurence K. J., Escabillas Cyrus G., Navarro Jose C.

Primary Institution: Zeenat Qureshi Stroke Institute Jose R. Reyes Memorial Medical Center

Hypothesis

The study aimed to evaluate the safety of intravenous edaravone for the treatment of acute ischemic stroke among Filipino patients.

Conclusion

The study found that edaravone has a favorable safety profile with mild side effects and no serious adverse events.

Supporting Evidence

  • 58 out of 64 patients completed the treatment without serious adverse effects.
  • Only mild side effects like headaches and dizziness were reported.
  • No serious adverse events occurred during the study.

Takeaway

This study looked at how safe a medicine called edaravone is for people having a stroke. Most people felt fine after taking it, with only a few mild headaches or dizziness.

Methodology

The study was a Phase IV, single-center, open-label, single-arm, prospective, longitudinal investigation assessing the safety of edaravone in treating acute ischemic stroke over 14 days.

Limitations

The study was limited to a single center and may not represent broader populations.

Participant Demographics

The majority of participants were male (60.34%), with a median age of 53.5 years, and 81.03% exhibited moderate stroke severity.

Digital Object Identifier (DOI)

10.1002/brb3.70158

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication